The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Opportunity to Advance hATTR Amyloidosis Research from Home
Prothena has teamed up with Sanguine, a provider of at-home clinical research services, to give you the opportunity to help advance hATTR Amyloidosis research from home.
FDA appoints Public Private Partnership Liaison to ARC
To focus on the challenges faced by AL amyloidosis, a particularly complex and multi-systemic disease, and bridge the gaps in drug discovery and development .